NCT04312503

Observational Study on the Effect of Switch to Lurasidone in Subjects With Schizophrenia"

Observational Study on the Effect of Switch to Lurasidone or Other Antipsychothics on Metabolic and Weight Changes in Subjects With Schizophrenia"

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 95 (actual)
• Sponsor: Aziende Chimiche Riunite Angelini Francesco S.p.A · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The aim of this study is observation, in an Italian real-world setting, of metabolic effects in patients with schizophrenia who will switch from any mono-therapy or poly-therapy antipsychotic regimen to monotherapy with lurasidone or to one of the other four most used atypical antipsychotics.

Detailed description

The aim of this study is the observation, in psychiatric Italian real-world settings, of metabolic effects, effectiveness, side effects and therapeutic adherence in patients with schizophrenia who switched, for any reason (efficacy, safety, metabolic problems, therapeutic adherence or patient's request), from any mono-therapy or poly-therapy antipsychotic regimen to monotherapy with lurasidone or with one of the four most used atypical antipsychotics in Italy (aripiprazole, olanzapine, quetiapine, risperidone). Patient's past medical and psychiatric history of the last 12 months will be also evaluated.

Conditions

• Schizophrenia

Interventions

Type	Name	Description
DRUG	Lurasidone	Patients are treated with dosages according clinical practice
DRUG	aripiprazole, olanzapine, quetiapine or risperidone	Patients are treated with dosages according clinical practice

Timeline

• Start date: 2020-07-13
• Primary completion: 2022-10-31
• Completion: 2022-10-31
• First posted: 2020-03-18
• Last updated: 2023-05-06

Locations

18 sites across 1 country: Italy